1 active not recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Active not recruiting 1 |
Follow Programmed Cell Death Protein 1 Inhibitor: new trials by email Literature Review of Programmed Cell Death Protein 1 Inhibitor trials Research Report on Programmed Cell Death Protein 1 Inhibitor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation Toripalimab, Gemcitabine, Cisplatin - Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor | Phase 2 | Active not recruiting | Sun Yat-sen University | 64 | 2023-12-01 | 2026-10-30 |
Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Male Urogenital Diseases (1) · Neoplasms (1) · Neoplasms by Site (1) · Urinary Bladder Diseases (1) · Urogenital Diseases (1) · Urogenital Neoplasms (1) · Urologic Diseases (1) · Urologic Neoplasms (1)
Carboplatin (1) · Cisplatin (1) · Gemcitabine (1) · Radiotherapy, Intensity-Modulated (1) · toripalimab (1)
China (1)
Yuanhong Gao, MD (1)